Inibizione enzimatica

Competitive inhibitors resemble the enzyme's substrate and bind to the active site, blocking substrate access and reducing available enzymes. Non-competitive inhibitors bind to allosteric sites away from the active site, changing the enzyme's shape and reducing substrate affinity. Both types regulate enzyme function but through different mechanisms and with distinct effects on reaction rates.

A competitive inhibitor does not prevent the enzyme from reaching Vmax, the maximum reaction rate. However, it requires more substrate and longer time to achieve this rate because substrate must outcompete the inhibitor for active site access. With sufficiently high substrate concentrations, the enzyme can still reach its maximum velocity.

Non-competitive inhibitors bind to allosteric sites and reduce the total number of functional enzymes available. Since they don't occupy the active site, adding more substrate cannot overcome their effect. The enzyme cannot achieve Vmax because the inhibitor permanently reduces the enzyme population capable of catalyzing the reaction.

Disulfiram is a competitive inhibitor used to treat chronic alcoholism. It binds to the active site of acetaldehyde dehydrogenase, preventing the conversion of acetaldehyde to acetyl coenzyme A. When alcohol is ingested, acetaldehyde accumulates, causing hangover-like symptoms that discourage alcohol consumption.

Reversible inhibitors interact with enzymes through weak interactions and are useful for regulating metabolic processes in normally functioning cells. Irreversible inhibitors form covalent bonds with enzymes, permanently blocking their function. Some toxins use irreversible inhibition, while regulatory inhibitors typically employ reversible binding for metabolic control.

Inhibitors reduce enzyme activity by binding to the enzyme, either at the active site or at allosteric sites. This regulation allows cells to control reaction rates and metabolic pathways. Drugs and toxins can also inhibit enzymes, making inhibition a critical mechanism for both normal cellular function and therapeutic intervention.

Cancer cells rely on enzymes regulating cell growth and division. Researchers explore molecules that competitively and non-competitively inhibit these growth-regulating enzymes to block cancer cell proliferation. By targeting specific enzymes with inhibitors, scientists can develop therapies that selectively suppress cancer cell activity while minimizing effects on normal cells.